Literature DB >> 3319136

Overview of current status and future direction of clinical trials with 5-fluorouracil in combination with folinic acid.

J L Grem1, D F Hoth, J M Hamilton, S A King, B Leyland-Jones.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3319136

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  17 in total

1.  Effects of 5-fluorouracil, leucovorin, and glucarate in rat colon-tumor explants.

Authors:  T D Schmittgen; A Koolemans-Beynen; T E Webb; T J Rosol; J L Au
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 2.  Preclinical development of eniluracil: enhancing the therapeutic index and dosing convenience of 5-fluorouracil.

Authors:  M T Paff; D P Baccanari; S T Davis; S Cao; R L Tansik; Y M Rustum; T Spector
Journal:  Invest New Drugs       Date:  2000-11       Impact factor: 3.850

Review 3.  5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development.

Authors:  J L Grem
Journal:  Invest New Drugs       Date:  2000-11       Impact factor: 3.850

4.  Biological modification of protracted infusion of 5-fluorouracil with weekly leucovorin. A dose seeking clinical trial for patients with disseminated gastrointestinal cancers.

Authors:  C G Leichman; L Leichman; C P Spears; P J Rosen; F Muggia; S Jeffers; W Waugh
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  In vitro splicing of pre-messenger RNA with extracts from 5-fluorouridine-treated cells.

Authors:  J R Patton
Journal:  Biochem J       Date:  1994-01-15       Impact factor: 3.857

6.  Phase I clinical trial of cisplatin given i.v. with 5-fluorouracil and high-dose folinic acid.

Authors:  J L Abbruzzese; R Amato; S Schmidt; M N Raber; P Frost
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

7.  Weekly 5-fluorouracil and high-dose folinic acid in combination with epidoxorubicin as first-line therapy in advanced breast cancer: a phase II study.

Authors:  H Stöger; T Bauernhofer; A K Kasparek; M Schmid; R Moser; F Ploner; E Derstvenscheg; I Kuss; M Wilders-Truschnig; P Steindorfer
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

8.  Biochemical modulation of 5-fluorouracil with or without leucovorin by a low dose of brequinar in MGH-U1 cells.

Authors:  T L Chen; C Erlichman
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

9.  Variations in patterns of DNA damage induced in human colorectal tumor cells by 5-fluorodeoxyuridine: implications for mechanisms of resistance and cytotoxicity.

Authors:  C E Canman; H Y Tang; D P Normolle; T S Lawrence; J Maybaum
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

10.  A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: a Southwest Oncology Group Study.

Authors:  Robert P Whitehead; Jacqueline K Benedetti; James L Abbruzzese; Bach Ardalan; J Wendall Goodwin; Stanley P Balcerzak; Wolfram E Samlowski; Heinz-Josef Lenz; John S Macdonald
Journal:  Invest New Drugs       Date:  2004-08       Impact factor: 3.850
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.